Table 2.
Baseline Characteristics
| Variables | Total N=192 |
|---|---|
| Age, mean | 60.5±10.2 |
| Female sex (%) | 56 (29.2) |
| BMI, kg/m2 | 27.9 (IQR 4.2) |
| Paroxysmal AF | 71 (37.4%) |
| Months in AF | 48 (IQR 84) |
| No. of DC conversions/patient with persistent AF | 3 (IQR 3) |
| Heredity (%) | 62 (32.6) |
| Hypertension (%) | 80 (42.1) |
| Diabetes mellitus (%) | 15 (7.8) |
| Heart failure (%) | 17 (8.9) |
| CKD (GFR <60 mL/min per 1.73 m2) (%) | 40 (20.1) |
| SVT (%) | 38 (19.8) |
| Stroke/TIA (%) | 19 (10) |
| CHA2DS2 VASc | 1.63 (IQR 2) |
| Beta‐blocker (%) | 139 (73.2) |
| AAD (%) | 105 (54.7) |
| Amiodarone (%) | 42 (22) |
| Flecainide (%) | 35 (18) |
| Dronedarone (%) | 23 (12.1) |
| ACEi or ARB (%) | 77 (48.5) |
| Statins (%) | 56 (29.5) |
| AF at the ablation lab (%) | 51 (27) |
| Arrival heart rate, bpm | 60 (IQR 22.5) |
| Procedural time, minute | 186±49.6 |
| Fluoroscopy time, minute | 21 (IQR 13) |
| Primary successful procedure (%) | 172 (90.5) |
| Complications (%) | 7 (3.7) |
| EF, % | 55.9±11.3 |
| LA volume, mL | 56.7±19.7 |
| E/E′ | 11.9 (IQR 6.1) |
Normally distributed continuous data are presented as means with SD; if not, they are presented as median values with IQR. Discrete data are presented as counts with percent values within brackets. AAD indicates antiarrhythmic drugs; ACEi, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; bpm, beats per minute; CHA2DS2 VASc, congestive heart failure, hypertension, age >75, diabetes, stroke, vascular disease, sex; CKD, chronic kidney failure; DC, direct current; EF, ejection fraction; GFR, glomerular filtration rate; IQR, interquartile range; LA, left atrium; SVT, supraventricular tachycardia; TIA, transient ischemic attack.